Phase 3: Effect of Diet, Physical Activity and Insulin Sensitizer Metformin on Obesity and Associated Risks in Children and Adolescents.
The Phase 3 trial conducted by the Lithuanian University of Health Sciences investigates the efficacy of Metformin in conjunction with lifestyle interventions (diet and physical activity) for treating obesity in children and adolescents. Given the rising prevalence of obesity and associated metabolic disorders in pediatric populations, successful outcomes could position Metformin as a first-line treatment option in this demographic, potentially expanding its market beyond adult diabetes management. The competitive landscape includes other anti-obesity medications and lifestyle intervention programs, necessitating a thorough analysis of efficacy, safety, and long-term outcomes to ensure a favorable market entry. Diligence should focus on regulatory pathways and reimbursement strategies for pediatric use.
Indication: Obesity
Modality: small molecule
Target: Insulin sensitivity modulation and metabolic profile improvement through the use of Metformin.
Sponsor: Lithuanian University of Health Sciences
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 18, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Insulin sensitivity modulation and metabolic profile improvement through the use of Metformin.
View original source fields
Condition raw: Obesity
Condition normalized: Obesity
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Insulin sensitivity modulation and metabolic profile improvement through the use of Metformin.
Target normalized: Insulin sensitivity modulation and metabolic profile improvement through the use of Metformin.